Group 1 - On July 22, 2025, the top three companies by trading volume in the Hong Kong Stock Connect (southbound) were Dongfang Electric (01072) with a trading volume of 4.374 billion, Huaxin Cement (06655) with 3.489 billion, and Tencent Holdings (00700) with 2.647 billion [1] - In the Shenzhen-Hong Kong Stock Connect (southbound), the top three companies by trading volume were SMIC (00981) with 1.979 billion, Meituan-W (03690) with 1.833 billion, and Alibaba-W (09988) with 1.739 billion [1] Group 2 - The top active companies in the Hong Kong Stock Connect (southbound) included Dongfang Electric (01072) with a net buy of 0.165 billion, Huaxin Cement (06655) with 0.313 billion, and Tencent Holdings (00700) with 0.271 billion [2] - In the Shenzhen-Hong Kong Stock Connect (southbound), SMIC (00981) had a net buy of 0.779 billion, while Meituan-W (03690) had a net sell of 0.050 billion [2]

| 6.08亿 | 4.51亿 | 10.59亿 +1.57亿 | | --- | --- | --- | | 小米集团-W 5.07亿 | 5.00亿 | 10.07亿 +670.13万 | | 中国龙工 4.09亿 | 4.10亿 | 8.18亿 -86.81万 | | 康方生物 HK 09926 HK 01810 HK 03339 | | | 智通财经APP获悉，7月22日港股市场，北水成交净买入27.17亿港元，其中港股通(沪)成交净买入29.85 亿港元，港股通(深)成交净卖出2.67亿港元。 北水净买入最多的个股是中国人寿(02628)、建设银行(00939)、中芯国际(00981)。北水净卖出最多的个 股是国泰君安国际(01788)、腾讯(00700)。 | 股票名称 | 买入额 | 卖出额 | 买卖总额 | | --- | --- | --- | --- | | | | | 净流入 | | 东方电气 | 22.70亿 | 21.05 乙 | 43.74 Z | | HK 01072 | | | +1.65 亿 | | 华新水泥 | 19.01亿 | 15.88 亿 | 34.89 乙 | | ...

Core Insights - Public funds continued to increase their holdings in Hong Kong stocks in Q2 2025, with the market value of Hong Kong stocks in the sample of actively managed equity funds rising to 20.0%, up from 19.2% in Q1 2025 [6][10] - The increase in holdings was primarily in small and medium-sized Hong Kong stocks, with the Hang Seng Small Cap Index's component stocks' market value share in the total Hong Kong stock holdings of funds increasing by 5.6 percentage points [6][10] - Sector-wise, public funds mainly increased their positions in the pharmaceutical, light manufacturing, non-bank financials, and banking sectors, corresponding to themes of innovative drugs, new consumption, and dividends [6][10] Fund Holdings Analysis - The report indicates a significant shift in fund holdings, with a reduction in the technology sector, particularly in internet and automotive stocks, which had previously seen substantial gains [6][10] - The technology sector's market value share in fund holdings decreased by 3.7 percentage points, while the media and retail sectors also saw declines [10][12] - Conversely, the consumer sector saw an increase of 3.8 percentage points in market value share, indicating a strategic pivot towards consumer-related investments [10][12] Specific Stock Movements - Notable changes in specific stock holdings include Tencent Holdings decreasing from 21.5% to 17.8%, while Alibaba's share dropped from 10.6% to 6.3% [12] - In contrast, stocks like Kuaishou and Pop Mart saw increases in their holdings, reflecting a shift towards emerging consumer brands [12] - The report highlights a significant increase in holdings for companies like Xinda Biopharmaceuticals, which rose from 1.2% to 3.5%, indicating a growing interest in innovative healthcare solutions [12]

Core Insights - Positive results from clinical trials can significantly impact pharmaceutical companies' stock prices, but long-term investors should consider broader factors for sustained performance [1] Eli Lilly - Eli Lilly reported positive phase 3 results for its oral GLP-1 candidate, orforglipron, focusing on diabetes patients with A1c reduction as the primary endpoint [4] - The company is expected to release data from late-stage studies for orforglipron in obesity within the next year, which could be pivotal for its market success [5] - Despite potential risks, Eli Lilly's stock is considered a buy due to its strong financial performance and a robust pipeline, including other candidates like retatrutide [6][7] Summit Therapeutics - Summit Therapeutics is developing ivonescimab, a cancer treatment already approved in China, and is conducting trials to support approval in the U.S. and Europe [8] - A key late-stage trial against Merck's Keytruda for non-small cell lung cancer (NSCLC) is ongoing, with top-line data expected by the end of next year [9] - The stock price is sensitive to trial results; positive outcomes could significantly boost the stock, while disappointing results may lead to declines [10][11] Vertex Pharmaceuticals - Vertex Pharmaceuticals focuses on developing breakthrough medicines for high unmet needs, including a candidate for type 1 diabetes (T1D), zimislecel, which shows promise in early trials [13] - In a phase 1/2 trial, 10 of 12 patients were insulin-free after one year, and the company plans to submit regulatory applications for zimislecel by 2026 [14] - Vertex continues to lead in cystic fibrosis treatments and has expanded its portfolio with new medicines, positioning itself well for future growth [15][16]

Group 1 - The report emphasizes that 2025 will be a significant year for small nucleic acid drug investments due to three major industry trends: the maturity of the GalNac delivery platform, the expansion of indications from rare diseases to common diseases, and the intensification of commercialization and clinical data catalysts for small nucleic acid drugs [2][12][27] - The GalNac delivery technology has matured, allowing for effective liver-targeting with lower toxicity compared to previous systems like LNP, which had issues with immune reactions and production complexity [2][21][38] - Small nucleic acid drugs are transitioning from treating rare diseases to addressing more prevalent conditions such as hyperlipidemia and hypertension, significantly expanding the potential patient population and market opportunities [2][12][27] Group 2 - Key catalysts for small nucleic acid drugs include the expected commercial launch of Novartis' Inclisiran, which is projected to accelerate sales, and the anticipated approvals of several products like Alnylam's Vutrisiran and Fitusiran [2][27][30] - The report highlights the strong stock performance of small nucleic acid companies in the U.S. market, with Alnylam, Arrowhead, and Ionis seeing significant price increases of 39.6%, 63.9%, and 59.9% respectively from their April lows to July 18 [12][9] - The report suggests focusing on domestic companies such as Heng Rui Medicine, Zhengda Tianqing, and Xinlitai, as well as international firms like Alnylam and Ionis, which are leading in the small nucleic acid space [2][46][37] Group 3 - The report identifies the GalNac platform as a key value driver, with products beginning to demonstrate their market potential, particularly in liver-targeting applications [21][22] - Alnylam is recognized as a leader in the small nucleic acid field, having successfully commercialized multiple siRNA drugs and demonstrating a high clinical success rate of 62%, significantly above the industry average [38][12] - The report notes that major pharmaceutical companies are increasingly interested in small nucleic acid technologies, indicating a strong potential for partnerships and licensing agreements in this area [37][46]

Group 1 - The core viewpoint of the article highlights that innovative drugs have become a key source of returns for public funds in 2023, with the Hong Kong stock market's innovative drug index surging by 93.94% as of July 21 [1] - A significant number of funds have reported exceptional performance, with six funds achieving over 100% returns, all heavily invested in innovative drugs [2][3] - The article emphasizes that the majority of funds with returns exceeding 80% are either actively or passively invested in the innovative drug sector [3] Group 2 - The pharmaceutical industry has faced a downturn since 2021, with the pharmaceutical and biotechnology index dropping over 40.19% and the Hong Kong innovative drug index declining by 59.24% over four years [5] - Despite the previous downturn, many funds have recovered losses from 2024 and generated substantial returns due to the recent surge in innovative drugs [6] - The article suggests that the current market rally may only be a temporary boost for thematic funds, and it is essential to evaluate long-term performance during previous downturns [7][8] Group 3 - The article provides detailed performance data of various funds, highlighting the returns of specific funds managed by notable fund managers, such as Zhang Wei and Jin Xiaofei, who have achieved significant returns through strategic investments in innovative drugs [11][37] - Zhang Wei's management of the Huatai-PineBridge Hong Kong Advantage Fund has yielded a return of 138.23% since its inception, while Jin Xiaofei's Penghua Medical Technology Fund has achieved a return of 260.27% since he took over [11][37] - The article discusses the investment strategies of these fund managers, focusing on their ability to identify undervalued innovative drug companies and their proactive adjustments to market conditions [15][56] Group 4 - The article mentions specific innovative drug companies that have performed well, such as Bai Li Tianheng and Hai Si Ke, which have seen significant stock price increases due to successful transitions from generic to innovative drug companies [24][63] - It highlights the importance of understanding the competitive landscape and long-term industry trends when investing in innovative drugs, as emphasized by fund managers like Zhao Wei [56][58] - The article concludes with a positive outlook for the innovative drug sector, suggesting that supportive policies and market conditions may lead to a recovery and growth in the coming years [34][49]

Core Insights - The successful launch of the drug Lisatoclax (also known as Lishengtuo) by Ascentage Pharma marks a significant milestone in the development of Bcl-2 inhibitors, breaking a nine-year monopoly held by AbbVie in this field [3][10] - The research on the Bcl-2 target has spanned over three decades, highlighting the challenges and complexities involved in drug development [3][5] - Ascentage Pharma aims to differentiate its products from existing therapies, focusing on innovative solutions to address unmet clinical needs [4][6] Company Overview - Ascentage Pharma's Lisatoclax is the first domestically developed Bcl-2 inhibitor in China and the second globally, showcasing the company's commitment to innovation [3][10] - The company has also developed another product, Olverembatinib (brand name: Nairike), which took 13 years to develop, further emphasizing its long-term investment in research [3] - The CEO of Ascentage Pharma, Yang Dajun, emphasizes the importance of targeting difficult drug targets and conducting rigorous clinical designs to achieve superior drug efficacy [4][6] Clinical Development - The Bcl-2 target is likened to PD-1 in blood cancer treatment, with the potential to treat various B-cell tumors effectively [5][6] - Lisatoclax has a unique dosing regimen that allows for a rapid escalation to the target dose, which is crucial for minimizing severe side effects like Tumor Lysis Syndrome (TLS) [6][7] - Clinical data suggest that Lisatoclax has a lower incidence of TLS compared to its competitors, enhancing its safety profile and making it a more convenient treatment option [6][7] Market Position and Strategy - Ascentage Pharma's stock has seen significant growth, with a year-to-date increase of over 70% in Hong Kong and more than 120% in the US market, indicating strong investor confidence [12] - The company aims to navigate the competitive landscape of innovative drugs by focusing on unique therapeutic targets rather than following trends in the market [12][13] - Yang Dajun believes that the current wave of innovation in the pharmaceutical industry is a result of accumulated experience, technological breakthroughs, and supportive policies [10][11] Future Outlook - Ascentage Pharma is optimistic about achieving profitability by 2027, reflecting its strategic focus on developing proprietary products that can generate revenue [13] - The company is positioned to capitalize on the evolving landscape of the biopharmaceutical industry, where the distinction between biotech and large pharmaceutical companies is increasingly defined by the ability to generate profits from self-developed products [13]

Group 1 - The Hong Kong stock market showed a collective increase, with the Hong Kong Stock Connect Innovation Drug ETF (159570) rising over 3%, and its trading volume exceeding 1 billion yuan, with a net inflow of nearly 5 billion yuan in the last 60 days [1] - As of July 18, the latest scale of the Hong Kong Stock Connect Innovation Drug ETF (159570) surpassed 10 billion yuan, setting a new historical record, leading in scale and liquidity among its peers [1] - The underlying index of the Hong Kong Stock Connect Innovation Drug ETF (159570) is fully invested in the innovative drug industry chain, with the top ten holdings accounting for nearly 72% of the total weight [6] Group 2 - The innovative drug sector is supported by a robust medical insurance fund structure, with total income projected at 34,913.37 billion yuan and total expenditure at 29,764.03 billion yuan by the end of 2024 [3] - Recent procurement policies favor innovative drugs, indicating a positive shift towards supporting new drug development, which is expected to enhance market demand and patient accessibility [3] - The global market for autoimmune disease treatments is projected to reach 119.35 billion USD by 2027, highlighting the significant growth potential in this sector [5] Group 3 - The Hong Kong Stock Connect Innovation Drug ETF (159570) has shown a remarkable increase of 62.78% in the first half of 2025, outperforming other medical indices [7] - The ETF's underlying assets are primarily Hong Kong stocks, allowing for T+0 trading, which enhances liquidity and trading flexibility [7] - The index has demonstrated strong performance over the past five years, with varying annual returns, indicating its resilience and growth potential in the innovative drug sector [8]

7月22日，港股创新药再度走强，高纯度+高弹性标的港股通创新药ETF（520880）场内价格现涨逾 3%，再攀新高。 | 序号 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 1513 | 丽珠医药 | 1 | 40.500 | 4 200 | | | 2 | 3933 | 联邦制药 | | 16.640 | 1.220 | 7.91% | | 3 | 9688 | 更鼎医药 | | 29.200 | 1.850 | 6.76% | | 4 | 1548 | 金斯瑞生物科技 | | 17.440 | 1.020 | 6.21% | | 5 | 9969 | 诺诚健华 | Mr. | 19.020 | 0.840 | 4.62% | | 6 | 9926 | 康方生物 | While | 146.900 | 6.400 | 4.56% | | 7 | 2162 | 康诺亚-B | | 62.650 | 2.550 | 4 74% | | 8 | 6990 | 科伦博泰生物-E W | | 39 ...

Group 1 - The Hang Seng Healthcare Index (HSHCI) has shown a strong increase of 2.14%, with notable gains from stocks such as Livzon Pharmaceutical (up 11.57%) and United Laboratories (up 7.00) [3] - The Hang Seng Healthcare ETF (513060) has risen by 2.02%, with a recent price of 0.66 yuan, and has accumulated an 8.95% increase over the past week, ranking in the top third among comparable funds [3] - The trading activity of the Hang Seng Healthcare ETF is robust, with a turnover rate of 10.09% and a transaction volume of 840 million yuan, indicating active market participation [3] Group 2 - The 11th batch of national drug procurement has officially launched, involving 55 varieties, signaling a positive shift in procurement policies favoring innovative drugs [4] - The procurement policy emphasizes "no procurement for new drugs" and optimizes selection criteria, enhancing protection for innovative drugs and promoting a healthier market ecosystem for generic drugs [4] - The stable operation of the national medical insurance fund, projected to reach total revenue of 34,913.37 billion yuan by the end of 2024, supports the accessibility and market demand for innovative drugs [5] Group 3 - The Hang Seng Healthcare ETF has seen a significant growth in scale, increasing by 221 million yuan over the past two weeks, ranking in the top third among comparable funds [5] - The ETF's financing activities are notable, with a latest financing purchase amount of 160 million yuan and a financing balance of 231 million yuan [5] - The ETF has achieved a net value increase of 30.39% over the past two years, with a maximum monthly return of 28.34% since inception [5] Group 4 - The Hang Seng Healthcare ETF has a Sharpe ratio of 2.22 over the past year, indicating strong risk-adjusted returns [6] - The ETF has the lowest relative drawdown among comparable funds, with a drawdown of 0.52% year-to-date [6] - The ETF's management fee is 0.50%, and its tracking error is 0.060%, the highest tracking precision among comparable funds [6] Group 5 - The top ten weighted stocks in the Hang Seng Healthcare Index account for 60.73% of the index, including companies like BeiGene and WuXi Biologics [7]